Family/Last name
Given name(s)
Patient identifiers
Date of request
Accession/Laboratory number
Elements in **black text** are **CORE**. Elements in **grey text** are **NON-CORE**.

### CLINICAL INFORMATION (select all that apply) (Note 1)

- **Information not provided**
- Relevant biopsy results, specify
- Previous diagnosis and treatment for oesophageal cancer, specify
- Endoscopic location of the tumour, specify levels (upper/middle/lower)
- Clinical staging, specify level of involvement, distant metastases
- History of gastroesophageal reflux and/or Barrett oesophagus
- Other (e.g., previous history of cancer), specify

### NEOADJUVANT THERAPY (Note 2)

- **Not administered**
- **Information not provided**
- Administered, describe

### OPERATIVE PROCEDURE (select all that apply) (Note 3)

- **Not specified**
- Pharyngo-laryngo-oesophagectomy
- Oesophagectomy/oesophagogastrectomy
- Lymph nodes, describe site(s) from which taken if sent separately by surgeon
- Other, specify

### SPECIMEN DIMENSIONS (Note 4)

<table>
<thead>
<tr>
<th>Specimen</th>
<th>Length of tubular oesophagus (Record per specimen)</th>
<th>Length of stomach, from oesophagogastric junction to distal gastric resection margin (if present)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Specimen 1</td>
<td>mm</td>
<td>mm</td>
</tr>
<tr>
<td>Specimen 2</td>
<td>mm</td>
<td></td>
</tr>
<tr>
<td>Specimen 3</td>
<td>mm</td>
<td></td>
</tr>
</tbody>
</table>

### MACROSCOPIC APPEARANCE (Note 5)

- No macroscopically detectable lesion
- Scar/thickening
- Protruding/fungating/polypoid
- Ulcerative tumour
- Diffuse infiltrative

### TUMOUR FOCALITY* (Note 6)

- Unifocal
- Multifocal, specify number of tumours in specimen
- Cannot be assessed, specify

* If multiple primary tumours are present, separate datasets should be used to record this and all following elements for each primary tumour.

### TUMOUR SITE (select all that apply) (Note 7)

- **Not specified**
- Cervical (proximal) oesophagus
- Upper thoracic oesophagus
- Middle thoracic oesophagus
- Lower thoracic (distal) oesophagus
- Oesophago gastric junction (OGJ) with tumour epicentre ≤ 20 mm into the proximal stomach
- Other, specify

Distance from epicentre/midpoint of tumour to OGJ mm
### TUMOUR DIMENSIONS (Note 8)

Maximum tumour dimension

<table>
<thead>
<tr>
<th>mm</th>
</tr>
</thead>
</table>

Additional dimensions

<table>
<thead>
<tr>
<th>mm</th>
<th>mm</th>
</tr>
</thead>
</table>

- No macroscopically visible tumour
- Cannot be assessed, specify

### BARRETT MUCOSA (Note 9)

- Not identified
- Present

### MACROSCOPIC DISTANCE OF TUMOUR TO THE MARGIN (Note 10)

- Cannot be assessed
- Involved
- Not involved

- Distance of tumour from closest margin

<table>
<thead>
<tr>
<th>mm</th>
</tr>
</thead>
</table>

Specify closest margin

### HISTOLOGICAL TUMOUR TYPE (Note 11)

*Value list based on the World Health Organization Classification of Tumours of the Digestive System (2019)*

- Cannot be assessed
- Squamous cell carcinoma
  - Conventional
  - Verrucous
  - Spindle cell carcinoma
  - Basaloid squamous cell carcinoma
- Adenocarcinoma
  - Tubular
  - Papillary
  - Mucinous
  - Poorly cohesive carcinoma
    - Signet ring
    - Non-signet ring
- Mucoepidermoid
- Adenosquamous carcinoma
- Adenoid cystic carcinoma
- Undifferentiated carcinoma
- Neuroendocrine neoplasms
  - Neuroendocrine carcinoma
    - Small cell
    - Large cell
    - Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN)
- Other, specify

### DYSPLASIA (Note 12)

- Not applicable
- Cannot be assessed
- Not identified
- Present

#### Type

- Squamous
- Columnar/Barrett

#### Grade

- Low grade
- High grade
- Cannot be assessed, specify

### HISTOLOGICAL TUMOUR GRADE (Note 13)

(Applicable to squamous cell carcinoma and adenocarcinoma)

- GX: Cannot be assessed
- Grade 1 (G1): Well differentiated
- Grade 2 (G2): Moderately differentiated
- Grade 3 (G3): Poorly differentiated

### EXTENT OF INVASION (Note 14)

- Cannot be assessed
- No evidence of primary tumour
- Dysplasia
- Invasion into the lamina propria
- Invasion into the muscularis mucosae
- Invasion into the submucosa
- Invasion into the muscularis propria
- Invasion into the adventitia
- Invasion into the visceral peritoneum, azygous vein, diaphragm, pleura, pericardium
- Invasion into adjacent structures/organs, specify

### LYMPHOVASCULAR INVASION (Note 15)

- Not identified
- Present (select all that apply)
  - Small vessel (lymphatic, capillary or venular), specify the type of vessel, if possible
  - Large vessel (venous)

### PERINEURAL INVASION (Note 16)

- Not identified
- Present

---

b  Neuroendocrine tumour is not covered in this dataset.
RESPONSE TO NEOADJUVANT THERAPY (Note 17)

- Cannot be assessed, specify

Mandard system
- Absence of residual cancer with fibrosis extending throughout (complete response)
- Rare residual cancer cells scattered through the fibrosis
- An increase in the number of residual cancer cells, but fibrosis still predominates
- Residual cancer outgrowing fibrosis
- Absence of regressive changes

Becker system
- No carcinoma present (complete response)
- <10% carcinoma present
- 10-50% carcinoma present
- >50% carcinoma present

OR

Modified Ryan system
- No neoadjuvant treatment
- Complete response - no viable cancer cells (score 0)
- Near complete response - single cells or rare small groups of cancer cells (score 1)
- Partial response - residual cancer with evident tumour regression, but more than single cells or rare small groups of cancer cells (score 2)
- Poor or no response - extensive residual cancer with no evident tumour regression (score 3)

MARGIN STATUS (Note 18)

Invasive carcinoma
- Cannot be assessed
- Not involved
  - Distance of tumour from closest margin
    - Specify closest margin, if possible
  - Involved (select all that apply)
    - Distal
    - Proximal
    - Circumferential/Radial

Dysplasia
- Cannot be assessed
- Not involved
  - Distance of dysplasia from closest margin
    - Specify closest margin, if possible
  - Involved
    - Squamous
      - High grade
      - Low grade
    - Columnar/Barrett
      - High grade
      - Low grade
    - Specify margin (select all that apply)
      - Distal
      - Proximal

LYMPH NODE STATUS (Note 19)

- Cannot be assessed
- No nodes submitted or found
  - Number of lymph nodes examined
  - Not involved
  - Involved
    - Number of involved lymph nodes

Extranodal extension
- Not identified
- Present
- Cannot be determined

COEXISTENT PATHOLOGY (select all that apply) (Note 20)

- None identified
- Synchronous carcinoma(s), specify
- Other, specify

ANCILLARY STUDIES (Note 21)

For neuroendocrine neoplasms only
- Not applicable
- Neuroendocrine markers (chromogranin A, synaptophysin, other), specify test(s) performed and result(s) if available

- AND
- Ki-67 proliferation index

Other oesophageal carcinomas
- Not performed
- PD-L1, specify
- Microsatellite instability, specify
- Other, specify test(s) and result(s)
### PATHOLOGICAL STAGING (UICC TNM 8th edition)\(^c\) (Note 23)\(^d\)

**TNM Descriptors** (only if applicable)
- No adjuvant therapy
- y - post-therapy

#### Primary tumour (pT)
- **TX** Primary tumour cannot be assessed
- **T0** No evidence of primary tumour
- **Tis** Carcinoma in situ/high grade dysplasia
- **T1** Tumour invades lamina propria, muscularis mucosae, or submucosa
  - **T1a** Tumour invades lamina propria or muscularis mucosae
  - **T1b** Tumour invades submucosa
- **T2** Tumour invades muscularis propria
- **T3** Tumour invades adventitia
- **T4** Tumour invades adjacent structures
  - **T4a** Tumour invades pleura, pericardium, azygos vein, diaphragm, or peritoneum
  - **T4b** Tumour invades other adjacent structures such as aorta, vertebral body, or trachea

#### Regional lymph nodes (pN)
- **NX** Regional lymph nodes cannot be assessed
- **N0** No regional lymph node metastasis
- **N1** Metastasis in 1 to 2 regional lymph nodes
- **N2** Metastasis in 3 to 6 regional lymph nodes
- **N3** Metastasis in 7 or more regional lymph nodes


\(^d\) Refer to Note for AJCC 8th Edition staging of oesophageal adenocarcinomas and squamous cell carcinomas with or without neoadjuvant therapy.
Definitions

CORE elements

CORE elements are those which are essential for the clinical management, staging or prognosis of the cancer. These elements will either have evidentiary support at Level III-2 or above (based on prognostic factors in the National Health and Medical Research Council (NHMRC) levels of evidence). In rare circumstances, where level III-2 evidence is not available an element may be made a CORE element where there is unanimous agreement in the expert committee. An appropriate staging system, e.g., Pathological TNM staging, would normally be included as a CORE element.

The summation of all CORE elements is considered to be the minimum reporting standard for a specific cancer.

NON-CORE elements

NON-CORE elements are those which are unanimously agreed should be included in the dataset but are not supported by level III-2 evidence. These elements may be clinically important and recommended as good practice but are not yet validated or regularly used in patient management.

Key information other than that which is essential for clinical management, staging or prognosis of the cancer such as macroscopic observations and interpretation, which are fundamental to the histological diagnosis and conclusion e.g., macroscopic tumour details, may be included as either CORE or NON-CORE elements by consensus of the Dataset Authoring Committee.

Scope

The dataset has been developed for the pathology reporting of resection specimens of the oesophagus. Carcinomas involving the oesophagogastric junction (OGJ) with tumour epicentre \( \leq 20 \) millimetres (mm) into the proximal stomach are included. A separate dataset is available for endoscopic resections of the oesophagus.

Neuroendocrine carcinomas (NECs) and mixed neuroendocrine-non-neuroendocrine neoplasms (MiNENs) of the oesophagus are included.

Well differentiated neuroendocrine tumours (NETs), non-epithelial malignancies such as melanoma, and secondary tumours are excluded from this dataset.
Note 1 – Clinical information (Non-core)

Clinical information can be provided by the clinician on the endoscopy report or the pathology request form. Pathologists may also search for additional information from previous pathology reports.

Relevant biopsy results include the presence of carcinoma, dysplasia (intraepithelial neoplasia), Barrett metaplasia, etc.

Endoscopic location or information regarding the location of the tumour from the clinician are an important guide as the specimen received may have retraction artefact after formalin fixation.

Information on clinical stage, such as the presence of distant metastases and involvement of adjacent structures, is essential information for the pathologist.

Multiple tumours may occur in the oesophagus and especially in patients with a previous history of cancer e.g., carcinoma of hypopharynx.

Back

Note 2 – Neoadjuvant therapy (Core)

Cancers with or without neoadjuvant therapy have different staging groups.²

Survival of patients with oesophageal adenocarcinoma after neoadjuvant chemotherapy/radiotherapy depends on the response to therapy.

Following neoadjuvant therapy, the extent of tumour regression is an important prognostic factor in both oesophageal squamous cell carcinoma and adenocarcinoma.³ ⁴ ⁵ ⁶ ⁷ In addition, tumour grade and lymph node downstaging following neoadjuvant therapy are also associated with disease-free survival in patients with oesophageal adenocarcinoma.

Back

Note 3 – Operative procedure (Core)

‘Oesophagectomy’ includes the oesophagus and a tiny strip of stomach and technically is also referred to as ‘oesophagogastrectomy’ which is removal of the oesophagus and the proximal portion of stomach.

The type of resection is a core element, as processing is different among different types of specimens. There is a general lack of uniformity as to the definition of the term lymphadenectomy in the context of oesophageal cancer surgery. For the purposes of this dataset the definitions standardised by the International Society of Diseases of the Esophagus and reviewed in Jamieson et al (2009) are used.⁹

A two-field lymphadenectomy refers to dissection of the mediastinum as well as the upper abdominal lymph nodes around the coeliac trifurcation. Three-field lymphadenectomy refers to the addition of bilateral cervical lymphadenectomy. Three-field lymphadenectomy is optimal for an
upper or middle thoracic oesophageal cancer with metastasis in the lymph node(s) based on improved long-term survival data. Therefore, the extent of lymphadenectomy should be recorded.\textsuperscript{9,10}

Ideally, lymph nodes should be submitted in groups and labelled separately by surgeons. It is otherwise difficult for pathologists to identify the different groups of lymph nodes.

\textbf{Note 4 – Specimen dimensions (Non-core)}

The dimensions of the specimen are normally measured to provide reference to the location of the tumour. It is noted that the oesophagus is approximately 25 centimetres (cm) in length. Record the specimen dimensions for each specimen.

If a specimen is received piecemeal and submitted in the one container, then a reconstructed measurement of size is recommended.

\textbf{Note 5 – Macroscopic appearance (Non-core)}

There is no evidence that macroscopic appearance has prognostic value in oesophageal cancer. However, the macroscopic appearance of the lesion, such as having an ulcerative appearance, could indicate the potential for a more advanced lesion.

The World Health Organization (WHO) descriptions for oesophageal squamous cell carcinoma are recommended.\textsuperscript{11}

In the WHO classification of oesophageal cancer, the macroscopic description for oesophageal adenocarcinoma is stricturing, polypoid, fungating, ulcerative, or diffuse infiltrating lesions whereas in squamous cell carcinoma, tumours are described as early versus advanced.\textsuperscript{11} Advanced squamous cell carcinoma is defined as protruding, ulcerative and localised, ulcerative and infiltrative as well as diffusely infiltrative.\textsuperscript{11} There is no WHO recommendation on the macroscopic description for other tumour types. However, there is no clinical significance attributed to these macroscopic features. In this dataset, we have unified the macroscopic descriptions to account for the effect of neoadjuvant therapies. It is worth noting that in specimens obtained post neoadjuvant therapy, there may be no macroscopically detectable lesion, or just a small scar seen.

\textbf{Note 6 – Tumour focality (Core)}

Multifocal oesophageal carcinomas should be documented. If there are synchronous primary lesions (i.e., two or more individual tumours), separate datasets should be used to record the tumour site and all following elements for each primary tumour.
Note 7 – Tumour site (Core and Non-core)

The location of the tumour is important for staging of oesophageal cancer.²

The location of a cancer is based on endoscopic examination and landmarks (Figures 1 and 2). Therefore, clinical information provided by the surgeon is critical.

The anatomical subdivisions of the oesophagus are outlined below (Figure 1):²

- The cervical oesophagus begins at the hypopharynx and extends to the thoracic inlet (at the level of the sternal notch); 15 to <20 cm from the incisors.
- Upper thoracic oesophagus extends from the thoracic inlet to the lower border of the azygos vein; 20 to <25 cm from the incisors.
- Middle thoracic oesophagus extends from the lower border of the azygos vein to the lower border of the inferior pulmonary vein; 25 to <30 cm from the incisors.
- Lower thoracic (distal) oesophagus extends from the lower border of the inferior pulmonary vein to the stomach, including the abdominal oesophagus; 30-40 cm from the incisors.
- Upper oesophagus is equal to cervical oesophagus and upper thoracic oesophagus.
- Middle oesophagus is equal to middle thoracic oesophagus.
- Lower oesophagus is equal to lower thoracic oesophagus or distal oesophagus.

In the absence of clinical information, the location of the tumour could be estimated from the relationship of the tumour to the OGJ junction by the pathologist. The epicentre/midpoint of the tumour should be considered as the point of measurement for the pathological examination. The exact distance of tumour from epicentre/midpoint to the OGJ is non-core because it is only for clinical correlation purposes.
A description of the tumour site is ideally provided by the surgeon and should be documented by the pathologist. In addition, specific observations should be recorded by the pathologist which may help establish the exact site of origin of the tumour.

The American Joint Committee on Cancer (AJCC) and College of American Pathologists (CAP) define the OGJ as the junction of the tubular oesophagus and the stomach, irrespective of the type of epithelial lining of the oesophagus.\textsuperscript{2,12}

Pure anatomical classification of the tumour site of origin can be defined in several different systems.

The Siewert classification categorises OGJ cancer into Siewert type I (tumours with their epicentre located 1-5 cm above the OGJ), type II (tumour epicentre located from 1 cm above to 2 cm below the OGJ) and type III (tumour epicentre located from 2 cm - 5 cm below the OGJ).\textsuperscript{13} In the Siewert classification, the proximal end of the gastric longitudinal mucosa folds is used as pragmatic reference for the endoscopic cardia/OGJ (zero point).\textsuperscript{13} The current Union for International Cancer Control (UICC)\textsuperscript{14}/AJCC\textsuperscript{2} 8\textsuperscript{th} Edition Staging System definition of gastric cancer includes those tumours involving the OGJ but with the epicentre >2 cm into the proximal stomach and cardia cancer without involvement of the OGJ (Figure 2). Therefore, all Siewert type III tumours are classified as gastric cancer based on the UICC\textsuperscript{14}/AJCC\textsuperscript{2} 8\textsuperscript{th} Edition Staging Systems.
Figure 2: (A) Oesophagogastric junction (OGJ) tumours with their epicentre located >2 cm into the proximal stomach are staged as stomach cancers. (B) Cardia cancers not involving the OGJ are staged as stomach cancers. (C) Tumours involving the OGJ with their epicentre <2 cm into the proximal stomach are staged as oesophageal cancer. Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the American Joint Committee on Cancer Staging Manual, Eighth Edition (2016) published by Springer Science+Business Media.²

The UICC¹⁴/AJCC² ⁸th Edition Staging Manuals also define tumours involving the OGJ as those with a midpoint within the proximal 20 mm of the cardia/proximal stomach and these are staged as oesophageal cancers. In contrast, tumours involving the OGJ with their epicentre more than 20 mm into the cardia/proximal stomach are staged as stomach cancers, as are all cardia/proximal stomach cancers not involving the OGJ, even if within 20 mm of the OGJ.²¹⁴

Some proximal stomach tumours which appear to be of gastric origin, under the AJCC ⁸th Edition classification, may be classified as tumours of the oesophagus and OGJ somewhat artificially and thus reported using the oesophageal dataset.² When reporting such tumours, it should be noted that the tumour may have arisen within the stomach.

A tumour arising from the oesophagus with a tumour epicentre beyond the 20 mm mark, is staged as a gastric tumour.

Note 8 – Tumour dimensions (Core and Non-core)

Where possible, the pathologist should record the maximum longitudinal dimension of the tumour mass and the distance of the tumour midpoint from the OGJ in the oesophagus and in the stomach.

If no tumour is macroscopically visible, or for small tumours where the macroscopic dimensions may not be accurate then the microscopic dimensions should be documented.
If the specimen is fragmented, measurements of the reconstructed tumour should be estimated, where possible. Otherwise, the clinical and/or radiological measurements should be used.

↑ Back

**Note 9 – Barrett mucosa (Non-core)**

The presence of Barrett mucosa points to the aetiology of the adenocarcinoma and helps to differentiate the origin of the lesion i.e., oesophageal versus gastric. The definition of Barrett mucosa varies between countries. In many regions, the presence of goblet cells is required for the diagnosis of Barrett mucosa.

Nevertheless, it is a non-core parameter on macroscopic examination as Barrett mucosa may be obscured by the cancer.

↑ Back

**Note 10 – Macroscopic distance of tumour to the margin (Core)**

A clear proximal resection margin may be difficult to obtain in oesophageal squamous cell carcinoma located in the upper portion. A positive resection margin is an important prognostic factor affecting survival rates.¹⁵

The distance of tumour from the closest resection margin, whether it is the distal, proximal or circumferential margin, should be recorded.

For tumours close to the resection margin an accurate macroscopic assessment may not be possible, and the microscopic measurement is used (see Note 18 MARGIN STATUS).

↑ Back

**Note 11 – Histological tumour type (Core)**

Pathological staging is different for the two major groups of oesophageal carcinomas, adenocarcinoma and squamous cell carcinoma.² It is important to refer to the current WHO Classification of Tumours of the Digestive System, ⁵th edition, 2019 (Table 1) for the different oesophageal malignant neoplasms.¹¹

Adenoid cystic carcinoma, undifferentiated carcinoma or NEC with an adenocarcinoma component use the adenocarcinoma stage grouping.¹⁶ There is no definite evidence for whether the staging of adenosquamous carcinoma or mucoepidermoid carcinoma should follow that of squamous cell carcinoma or adenocarcinoma staging groups.¹¹

For adenocarcinoma, there are different histological patterns. In most instances, they could be grouped either into tubular, papillary and mucinous patterns. In rare circumstances, the tumour could be poorly cohesive and have either signet ring or non-signet ring pattern.

In MiNEN of the oesophagus, the neuroendocrine component is nearly always NEC.
Table 1: World Health Organization classification of tumours of the oesophagus.11

<table>
<thead>
<tr>
<th>Descriptor</th>
<th>ICD-O codes⁵</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Benign epithelial tumours and precursors</strong></td>
<td></td>
</tr>
<tr>
<td>Squamous cell papilloma NOS</td>
<td>8052/0</td>
</tr>
<tr>
<td>Squamous papillomatosis</td>
<td>8060/0</td>
</tr>
<tr>
<td>Oesophageal glandular dysplasia (intraepithelial neoplasia), low grade</td>
<td>8148/20</td>
</tr>
<tr>
<td>Oesophageal glandular dysplasia (intraepithelial neoplasia), high grade</td>
<td>8148/2</td>
</tr>
<tr>
<td>Oesophageal squamous intraepithelial neoplasia (dysplasia), low grade</td>
<td>8077/0</td>
</tr>
<tr>
<td>Oesophageal squamous intraepithelial neoplasia (dysplasia), low grade</td>
<td>8077/2</td>
</tr>
<tr>
<td><strong>Malignant epithelial tumours</strong></td>
<td></td>
</tr>
<tr>
<td>Adenocarcinoma NOS</td>
<td>8140/3</td>
</tr>
<tr>
<td>Adenoid cystic carcinoma</td>
<td>8200/3</td>
</tr>
<tr>
<td>Mucoepidermoid carcinoma</td>
<td>8430/3</td>
</tr>
<tr>
<td>Adenosquamous carcinoma</td>
<td>8560/3</td>
</tr>
<tr>
<td>Squamous cell carcinoma NOS</td>
<td>8070/3</td>
</tr>
<tr>
<td>Verrucous squamous cell carcinoma</td>
<td>8051/3</td>
</tr>
<tr>
<td>Squamous cell carcinoma, spindle cell</td>
<td>8074/3</td>
</tr>
<tr>
<td>Basaloid squamous cell carcinoma</td>
<td>8083/3</td>
</tr>
<tr>
<td>Carcinoma, undifferentiated, NOS</td>
<td>8020/3</td>
</tr>
<tr>
<td>Lymphoepithelioma-like carcinoma</td>
<td>8082/3</td>
</tr>
<tr>
<td><strong>Neuroendocrine tumour</strong></td>
<td></td>
</tr>
<tr>
<td>Neuroendocrine tumour NOS</td>
<td>8240/3</td>
</tr>
<tr>
<td>Neuroendocrine tumour, grade 1</td>
<td>8240/3</td>
</tr>
<tr>
<td>Neuroendocrine tumour, grade 2</td>
<td>8249/3</td>
</tr>
<tr>
<td>Neuroendocrine tumour, grade 3</td>
<td>8249/3</td>
</tr>
<tr>
<td>Neuroendocrine carcinoma NOS</td>
<td>8246/3</td>
</tr>
<tr>
<td>Large cell neuroendocrine carcinoma</td>
<td>8013/3</td>
</tr>
<tr>
<td>Small cell neuroendocrine carcinoma</td>
<td>8041/3</td>
</tr>
<tr>
<td>Mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN)</td>
<td>8154/3</td>
</tr>
<tr>
<td>Combined small cell-adenocarcinoma</td>
<td>8045/3</td>
</tr>
<tr>
<td>Combined small cell-squamous cell carcinoma</td>
<td>8045/3</td>
</tr>
</tbody>
</table>

⁵ These morphology codes are from the International Classification of Diseases for Oncology, Third Edition, second revision (ICD-O-3.2).¹⁷ Behaviour is coded /0 for benign tumours; /1 for unspecified, borderline, or uncertain behaviour; /2 for carcinoma in situ and grade III intraepithelial neoplasia; and /3 for malignant tumours, primary site; and /6 for malignant tumours, metastatic site.

Note 12 – Dysplasia (Core)

There are two types of dysplasia, squamous dysplasia and columnar/glandular (either Barrett or non-Barrett) dysplasia.

In the current WHO classification, both squamous and Barrett dysplasia are classified using a two-tiered system, high and low grade.11

Columnar dysplasia is mostly Barrett dysplasia. The presence of Barrett dysplasia supports oesophageal origin of an adenocarcinoma.

The term Barrett dysplasia in the WHO classification is adopted because of the aetiological link with Barrett oesophagus. However, it is noted that rare cases of oesophageal adenocarcinoma may not arise from Barrett dysplasia. For instance, some rare adenocarcinomas of the mid oesophagus have no relationship with Barrett dysplasia.11

Oesophageal columnar neoplasia is broadly divided into gastric, intestinal and mixed (hybrid) types, based on morphological and immunohistochemical features.11 The clinical significance of this division is yet to be determined and is not needed for routine clinical care.

Squamous dysplasia may present adjacent to squamous carcinoma in the upper oesophagus. Due to the anatomical limit of resection, dysplasia may extend to the proximal resection margin.

Back

Note 13 – Histological tumour grade (Core)

Grade (differentiation) of the tumour contributes to pathological staging or pathological prognostic grouping.2

The 5th Edition of the WHO classification has defined the morphological criteria for grading of adenocarcinoma and squamous cell carcinoma.11

In adenocarcinoma, grade 1 is defined as adenocarcinoma with >95% of the carcinoma with well-formed glands; grade 2 with 50% to 95% with well-formed glands; grade 3 is <50% with glandular formation.16

In squamous cell carcinoma, grade 1 to grade 3 depends on the amount of keratin pearls, cytological atypia, mitotic activity and proportion of basaloid cells.18

The three-tiered grading is preferred to the two-tiered system as each grade may have an impact on early staged oesophageal cancers not treated by pre-operative adjuvant therapy based on AJCC stage grouping.

It is acknowledged that after neoadjuvant therapy, it may be difficult to grade the carcinoma. However, this does not impact pathological staging.

Histological tumour grade is applicable to squamous cell carcinoma and adenocarcinoma only.

Back
Note 14 – Extent of invasion (Core)

The UICC\textsuperscript{14}/AJCC\textsuperscript{3} 8\textsuperscript{th} Edition Staging Manuals divide T stage into T1a and T1b. T1a refers to invasion into the lamina propria or muscularis mucosae whereas T1b involves the submucosa (Figures 3 and 4). Thus, the extent of invasion must be recorded accurately.

Figure 3: Microscopic anatomy of the oesophagus. Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the American Joint Committee on Cancer Staging Manual, Eighth Edition (2016) published by Springer Science+Business Media.\textsuperscript{2}

Figure 4: Anatomic cancer classification is by depth of cancer invasion (T) and regional lymph node classification (N), defined by absence (N0) or presence (N1) of cancer-positive lymph nodes. Distant metastasis (M) not illustrated. Reproduced with permission from Ishwaran H et al (2009). A novel approach to cancer staging: application to oesophageal cancer. Biostatistics 10(4):603-620 by permission of Oxford University Press.\textsuperscript{19}
**Note 15 – Lymphovascular invasion (Core)**

Lymphovascular invasion is a known poor prognostic factor in oesophageal carcinomas and is designated a core element.\(^{11}\)

The value of subdividing lymphovascular invasion into large vessel (venous) and small vessels (lymphatic, capillary and venular) has not been investigated. However, recording of this type of data will be useful to aid further investigation. Identifying invasion into the extramural veins is important.

[Back]

**Note 16 – Perineural invasion (Non-core)**

The existence of perineural infiltration after neoadjuvant treatment is closely associated with poor prognosis and could be utilised along with the Tumour-Node-Metastasis (TNM) staging system for better discrimination between patients with oesophageal squamous cell carcinoma or adenocarcinoma.\(^{20,21}\)

However, as more studies are needed to validate the impact of perineural invasion, it is designated as a non-core parameter.

[Back]

**Note 17 – Response to neoadjuvant therapy (Core)**

There are two commonly used systems to assess tumour regression grade (Table 2). One very common method employed to assess tumour regression is the Mandard classification system (Table 2).\(^{22}\) This five-tiered system divides tumour regression into five grades based on the proportion of viable tumour tissue present in relation to fibrosis.\(^{22}\)

There is also a four-tiered system (Becker system) recommended by some authors for having a better reproducibility for pathological assessment (Table 2).\(^{23}\) This system depends on the proportion of residual cancer cells present by percentage.

The modified Ryan system\(^{24}\) proposed by the CAP\(^{12}\) (Table 3), recognises four grades based on the proportion of residual tumour in a descriptive manner, but this is less commonly adopted in oesophageal cancers.

Although many studies have evaluated and compared these schemes in assessing treatment response in gastrointestinal carcinomas after neoadjuvant therapy, there is no consensus on the optimal way to stratify tumour regression grades. In addition, the inter- and intra-observer variability is high in most schemes. Nevertheless, response to neoadjuvant therapy should be reported, as assessment of histological tumour regression may provide valuable prognostic information and impact on the choice of postoperative therapy.\(^{21}\) Patients with complete tumour regression have significantly better overall survival compared to patients with residual adenocarcinoma. As there is no current consensus on grading schemes, the three most commonly used systems have been provided by the Carcinoma of the Oesophagus Dataset Authoring Committee.\(^{6,22,24}\) Subjective elements in interpretation are difficult to avoid. Further comparative studies are needed.
However, regardless of the system used, it is important to assess the tumour regression grade as it is associated with prognosis in patients with oesophageal carcinomas.  

**Table 2: The Mandard and Becker systems for assessing the tumour regression grade (TRG) of carcinoma after neoadjuvant therapy.**

<table>
<thead>
<tr>
<th>Mandard</th>
<th>Becker</th>
</tr>
</thead>
<tbody>
<tr>
<td>TRG 1: Absence of residual cancer, with fibrosis extending through the various layers of the oesophageal wall (complete regression)</td>
<td>TRG 1a: No residual carcinoma present</td>
</tr>
<tr>
<td>TRG 2: Rare residual cancer cells scattered through the fibrosis</td>
<td>TRG 1b: &lt;10% residual carcinoma present</td>
</tr>
<tr>
<td>TRG 3: An increase in the number of residual cancer cells, but fibrosis still predominates</td>
<td>TRG 2: 10-50% residual carcinoma present</td>
</tr>
<tr>
<td>TRG 4: Residual cancer outgrowing fibrosis</td>
<td>TRG 3: &gt;50% residual carcinoma present</td>
</tr>
<tr>
<td>TRG 5: Absence of regressive changes</td>
<td></td>
</tr>
</tbody>
</table>

© World Health Organization/International Agency for Research on Cancer.

**Table 3: Modified Ryan scheme for tumour regression grading system.**

<table>
<thead>
<tr>
<th>Description</th>
<th>Tumour Regression Score</th>
</tr>
</thead>
<tbody>
<tr>
<td>No viable cancer cells (complete response)</td>
<td>0</td>
</tr>
<tr>
<td>Single cells or rare small groups of cancer cells (near complete response)</td>
<td>1</td>
</tr>
<tr>
<td>Residual cancer with evident tumour regression, but more than single cells or rare small groups of cancer cells (partial response)</td>
<td>2</td>
</tr>
<tr>
<td>Extensive residual cancer with no evident tumour regression (poor or no response)</td>
<td>3</td>
</tr>
</tbody>
</table>


**Note 18 – Margin status** (Core)

The proximal resection margin is important in oesophageal squamous cell carcinoma due to the anatomical limit for resection.

In many studies, the circumferential margin is associated with a poorer outcome for patients with oesophageal carcinomas.

There is controversy in defining when to call a circumferential margin positive, with some labelling margins of <1 mm positive and others defining it as the presence of tumour cells at the resection margin. No consensus has been reached. When patients with a positive circumferential margin via
either definition were compared with those with a margin clearance of >1 mm, overall survival was significantly prolonged in the latter.  

For multifocal tumours, the presence of positive margin in any tumour should be indicated as ‘positive’, and the closest margin can be measured from any tumour in the specimen.

**Note 19 – Lymph node status** (Core and Non-core)

The number of lymph nodes infiltrated by carcinoma is a core element. More important is the minimum number of lymph nodes sampled for accurate assessment. The UICC\textsuperscript{14}/AJCC\textsuperscript{2} classification system N3, is 7 or more lymph nodes.

According to UICC\textsuperscript{14}/AJCC\textsuperscript{2} 8\textsuperscript{th} Editions, although it is suggested that at least 16 regional lymph nodes (Figure 5) be removed and assessed pathologically, removal and evaluation of greater than or equal to 30 nodes is desirable due to the prognostic value of increased nodal yield on overall survival.\textsuperscript{4,29,30}

The presence or absence of regressive changes observed in lymph node metastases could be recorded, as there is some evidence that this has a prognostic impact.\textsuperscript{31-34}

Like the situation in squamous cell carcinomas in the head and neck region, extranodal extension in oesophageal squamous carcinoma was shown to have prognostic impact for patients.\textsuperscript{35} Nevertheless, more studies are needed to validate the use of extranodal extension as a prognostic marker, and it is therefore a non-core element.

**Figure 5: Regional lymph nodes of the oesophagus.** Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the American Joint Committee on Cancer Staging Manual, Eighth Edition (2016) published by Springer Science+Business Media.\textsuperscript{2}
Note 20 – Coexistent pathology (Non-core)

Common coexisting pathology other than Barrett oesophagus may include scar tissue, leiomyoma, squamous papilloma, etc.

Back

Note 21 – Ancillary studies (Core and Non-core)

For oesophageal neuroendocrine carcinomas including mixed neuroendocrine-non-neuroendocrine carcinomas (MiNECs), the reporting of neuroendocrine marker expression and Ki-67 proliferation index are core elements. These elements are non-core for other types of oesophageal carcinomas. Neuroendocrine neoplasms are classified into NETs, NECs and MiNENs. NETs are graded 1-3 using the mitotic count and Ki-67 proliferation index but pure NETs are not considered within the scope of this dataset. Most NECs show marked cytological atypia, brisk mitotic activity, and are subclassified into small cell and large cell subtypes. NECs are considered high grade by definition. MiNENs are usually composed of a poorly differentiated NEC component and an adenocarcinoma component. If a pure or mixed NEC is suspected on morphology, immunohistochemistry is required to confirm neuroendocrine differentiation, usually applying synaptophysin and chromogranin A as a minimum. HER2 is important for planning therapy for metastatic or unresectable OGI adenocarcinoma. It should be tested by immunohistochemistry and could be confirmed by in situ hybridisation.

PD-L1 or microsatellite instability markers are helpful in predicting response to immunotherapy. They may be considered if immunotherapy is to be used for treatment of advanced oesophageal carcinoma.

Neuroendocrine neoplasms often need to be confirmed by neuroendocrine markers such as chromogranin and synaptophysin.

Back

Note 22 – Histologically confirmed distant metastases (Core)

The presence of distant metastases is one of the most important parameters for staging of patients with oesophageal carcinomas.

Back

Note 23 – Pathological staging (Core)

Pathological staging (according to the agreed criteria of the UICC and AJCC 8th Editions) is the most important factor to predict the survival of patients with oesophageal carcinomas.

It is worth noting that although the pathological criteria T, N, M remain the same, the stage grouping is different from squamous cell carcinoma and adenocarcinoma. Stage grouping tables have therefore been provided for reference (see Tables 4-7) for the AJCC 8th Edition staging of
oesophageal adenocarcinomas and squamous cell carcinomas with or without neoadjuvant therapy. The differentiation (grades) of the carcinomas are important criteria for the stage grouping.

In the AJCC 8th Edition Staging Manual there is only one staging grouping for both squamous cell carcinoma and adenocarcinoma. The stage grouping is different from that without therapy. The grade of carcinoma is not a criterion for the stage grouping.

Table 4: American Joint Committee on Cancer Pathological (pTNM) – Squamous cell carcinoma.

<table>
<thead>
<tr>
<th>When pT is...</th>
<th>And pN is...</th>
<th>And M is...</th>
<th>And G is...</th>
<th>And location is...</th>
<th>Then the stage group is...</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
<td>N/A</td>
<td>Any</td>
<td>0</td>
</tr>
<tr>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
<td>G1</td>
<td>Any</td>
<td>IA</td>
</tr>
<tr>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
<td>G2-3</td>
<td>Any</td>
<td>IB</td>
</tr>
<tr>
<td>T1b</td>
<td>N0</td>
<td>M0</td>
<td>GX</td>
<td>Any</td>
<td>IA</td>
</tr>
<tr>
<td>T1b</td>
<td>N0</td>
<td>M0</td>
<td>G1-3</td>
<td>Any</td>
<td>IB</td>
</tr>
<tr>
<td>T2</td>
<td>N0</td>
<td>M0</td>
<td>G1</td>
<td>Any</td>
<td>IB</td>
</tr>
<tr>
<td>T2</td>
<td>N0</td>
<td>M0</td>
<td>G2-3</td>
<td>Any</td>
<td>IIA</td>
</tr>
<tr>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td>G1-3</td>
<td>Lower</td>
<td>IIA</td>
</tr>
<tr>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td>G1</td>
<td>Upper/middle</td>
<td>IIA</td>
</tr>
<tr>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td>G2-3</td>
<td>Upper/middle</td>
<td>IIB</td>
</tr>
<tr>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td>GX</td>
<td>Lower/upper/middle</td>
<td>IIB</td>
</tr>
<tr>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td>GX</td>
<td>Location X</td>
<td>IIB</td>
</tr>
<tr>
<td>T1</td>
<td>N1</td>
<td>M0</td>
<td>Any</td>
<td>Any</td>
<td>IIB</td>
</tr>
<tr>
<td>T1</td>
<td>N2</td>
<td>M0</td>
<td>Any</td>
<td>Any</td>
<td>IIIA</td>
</tr>
<tr>
<td>T2</td>
<td>N1</td>
<td>M0</td>
<td>Any</td>
<td>Any</td>
<td>IIIA</td>
</tr>
<tr>
<td>T2</td>
<td>N2</td>
<td>M0</td>
<td>Any</td>
<td>Any</td>
<td>IIIB</td>
</tr>
<tr>
<td>T3</td>
<td>N1-2</td>
<td>M0</td>
<td>Any</td>
<td>Any</td>
<td>IIIB</td>
</tr>
<tr>
<td>T4a</td>
<td>N0-1</td>
<td>M0</td>
<td>Any</td>
<td>Any</td>
<td>IIIB</td>
</tr>
<tr>
<td>T4a</td>
<td>N2</td>
<td>M0</td>
<td>Any</td>
<td>Any</td>
<td>IVA</td>
</tr>
<tr>
<td>T4b</td>
<td>N0-2</td>
<td>M0</td>
<td>Any</td>
<td>Any</td>
<td>IVA</td>
</tr>
<tr>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
<td>Any</td>
<td>Any</td>
<td>IVA</td>
</tr>
<tr>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
<td>Any</td>
<td>Any</td>
<td>IVB</td>
</tr>
</tbody>
</table>

Table 5: American Joint Committee on Cancer Postneoadjuvant Therapy (ypTNM) – Squamous cell carcinoma.

<table>
<thead>
<tr>
<th>When yp T is...</th>
<th>And yp N is...</th>
<th>And M is...</th>
<th>Then the stage group is...</th>
</tr>
</thead>
<tbody>
<tr>
<td>T0-2</td>
<td>N0</td>
<td>M0</td>
<td>I</td>
</tr>
<tr>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td>II</td>
</tr>
<tr>
<td>T0-2</td>
<td>N1</td>
<td>M0</td>
<td>IIA</td>
</tr>
<tr>
<td>T3</td>
<td>N1</td>
<td>M0</td>
<td>IIIB</td>
</tr>
<tr>
<td>T0-3</td>
<td>N2</td>
<td>M0</td>
<td>IIIB</td>
</tr>
<tr>
<td>T4a</td>
<td>N0</td>
<td>M0</td>
<td>IIIB</td>
</tr>
<tr>
<td>T4a</td>
<td>N1-2</td>
<td>M0</td>
<td>IVA</td>
</tr>
<tr>
<td>T4a</td>
<td>NX</td>
<td>M0</td>
<td>IVA</td>
</tr>
<tr>
<td>T4b</td>
<td>N0-2</td>
<td>M0</td>
<td>IVA</td>
</tr>
<tr>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
<td>IVA</td>
</tr>
<tr>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
<td>IVB</td>
</tr>
</tbody>
</table>

Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the American Joint Committee on Cancer Staging Manual, Eighth Edition (2016) published by Springer Science+Business Media.²

Table 6: American Joint Committee on Cancer Pathological (pTNM) – Adenocarcinoma.

<table>
<thead>
<tr>
<th>When pT is...</th>
<th>And pN is...</th>
<th>And M is...</th>
<th>And G is...</th>
<th>Then the stage group is...</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tis</td>
<td>N0</td>
<td>M0</td>
<td>N/A</td>
<td>0</td>
</tr>
<tr>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
<td>G1</td>
<td>IA</td>
</tr>
<tr>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
<td>GX</td>
<td>IA</td>
</tr>
<tr>
<td>T1a</td>
<td>N0</td>
<td>M0</td>
<td>G2</td>
<td>IB</td>
</tr>
<tr>
<td>T1b</td>
<td>N0</td>
<td>M0</td>
<td>G1-2</td>
<td>IB</td>
</tr>
<tr>
<td>T1b</td>
<td>N0</td>
<td>M0</td>
<td>GX</td>
<td>IB</td>
</tr>
<tr>
<td>T1</td>
<td>N0</td>
<td>M0</td>
<td>G3</td>
<td>IC</td>
</tr>
<tr>
<td>T2</td>
<td>N0</td>
<td>M0</td>
<td>G1-2</td>
<td>IC</td>
</tr>
<tr>
<td>T2</td>
<td>N0</td>
<td>M0</td>
<td>G3</td>
<td>IIA</td>
</tr>
<tr>
<td>T2</td>
<td>N0</td>
<td>M0</td>
<td>GX</td>
<td>IIA</td>
</tr>
<tr>
<td>T2</td>
<td>N1</td>
<td>M0</td>
<td>Any</td>
<td>IIB</td>
</tr>
<tr>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td>Any</td>
<td>IIB</td>
</tr>
<tr>
<td>T1</td>
<td>N2</td>
<td>M0</td>
<td>Any</td>
<td>IIIA</td>
</tr>
<tr>
<td>T1</td>
<td>N1</td>
<td>M0</td>
<td>Any</td>
<td>IIIA</td>
</tr>
<tr>
<td>T2</td>
<td>N2</td>
<td>M0</td>
<td>Any</td>
<td>IIIA</td>
</tr>
<tr>
<td>T3</td>
<td>N1-2</td>
<td>M0</td>
<td>Any</td>
<td>IIIB</td>
</tr>
<tr>
<td>T4a</td>
<td>N0-1</td>
<td>M0</td>
<td>Any</td>
<td>IIIB</td>
</tr>
<tr>
<td>T4a</td>
<td>N2</td>
<td>M0</td>
<td>Any</td>
<td>IVA</td>
</tr>
<tr>
<td>T4b</td>
<td>N0-2</td>
<td>M0</td>
<td>Any</td>
<td>IVA</td>
</tr>
<tr>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
<td>Any</td>
<td>IVA</td>
</tr>
<tr>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
<td>Any</td>
<td>IVB</td>
</tr>
</tbody>
</table>

Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the American Joint Committee on Cancer Staging Manual, Eighth Edition (2016) published by Springer Science+Business Media.²
Table 7: American Joint Committee on Cancer Postneoadjuvant Therapy (ypTNM) – Adenocarcinoma.

<table>
<thead>
<tr>
<th>When yp T is...</th>
<th>And yp N is...</th>
<th>And M is...</th>
<th>Then the stage group is...</th>
</tr>
</thead>
<tbody>
<tr>
<td>T0-2</td>
<td>N0</td>
<td>M0</td>
<td>I</td>
</tr>
<tr>
<td>T3</td>
<td>N0</td>
<td>M0</td>
<td>II</td>
</tr>
<tr>
<td>T0-2</td>
<td>N1</td>
<td>M0</td>
<td>IIIA</td>
</tr>
<tr>
<td>T3</td>
<td>N1</td>
<td>M0</td>
<td>IIIB</td>
</tr>
<tr>
<td>T4a</td>
<td>N0</td>
<td>M0</td>
<td>IIIB</td>
</tr>
<tr>
<td>T4a</td>
<td>N1-2</td>
<td>M0</td>
<td>IVA</td>
</tr>
<tr>
<td>T4a</td>
<td>NX</td>
<td>M0</td>
<td>IVA</td>
</tr>
<tr>
<td>T4b</td>
<td>N0-2</td>
<td>M0</td>
<td>IVA</td>
</tr>
<tr>
<td>Any T</td>
<td>N3</td>
<td>M0</td>
<td>IVA</td>
</tr>
<tr>
<td>Any T</td>
<td>Any N</td>
<td>M1</td>
<td>IVB</td>
</tr>
</tbody>
</table>

Used with permission of the American College of Surgeons, Chicago, Illinois. The original source for this information is the American Joint Committee on Cancer Staging Manual, Eighth Edition (2016) published by Springer Science+Business Media.1

References


